Avicanna Inc.

Equities

AVCN

CA05368K1003

Biotechnology & Medical Research

Delayed Toronto S.E. Other stock markets 11:02:31 2024-06-12 EDT			5-day change	1st Jan Change
0.255 ^CAD	+2.00%		+8.51%	-27.14%

05-14	Avicanna Up 4.5% as it Books Record Q1 Revenue, First Adjusted EBITDA Positive Quarter in Company History	MT
05-14	Avicanna Books Record Q1 Revenue, First Adjusted Ebitda Positive Quarter in Company History	MT

Avicanna LATAM S.A.S. Announces Step Down of Lucas Nosiglia as President, Effective January 31, 2023

December 30, 2022 at 07:33 am

Avicanna Inc. announced an organizational change in Avicanna LATAM S.A.S. with Lucas Nosiglia stepping down as President of Avicanna LATAM S.A.S. effective January 31, 2023 and transitioning to another role within the Company.

Latest news about Avicanna Inc.

Avicanna Up 4.5% as it Books Record Q1 Revenue, First Adjusted EBITDA Positive Quarter in Company History	05-14	MT
Avicanna Books Record Q1 Revenue, First Adjusted Ebitda Positive Quarter in Company History	05-14	MT
Avicanna Brief: Record Q1 revenue of $6.45 million representing a year-over-year increase of 451% compared to Q1 2023	05-14	MT
Avicanna Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024	05-13	CI
Avicanna Announced Results of Study in Patients with Epidermolysis Bullosa	05-13	MT
Avicanna Brief: Announcing Results of Study in Patients with Epidermolysis Bullosa	05-13	MT
Avicanna Inc. Announces Results of Study in Patients with Epidermolysis Bullosa	05-13	CI
Avicanna Raises About $2.1 Million in Non-brokered Private Placement	04-19	MT
Avicanna Inc. announced that it has received CAD 2.125584 million in funding	04-17	CI
Avicanna Inc. Announces Completion of Topical Gel Observational Real-World Evidence Study	04-10	CI
Transcript : Avicanna Inc., 2023 Earnings Call, Apr 02, 2024	04-02
Avicanna's Q4 Loss Narrows, Revenue Grows	04-02	MT
Avicanna Brief: Reporting $16.8 Million in 2023 Revenue, representing an increase of 314% from 2022	04-02	MT
Avicanna Inc. Reports Earnings Results for the Full Year Ended December 31, 2023	04-01	CI
Avicanna Announced Canadian Launch of 10% CBD (THC Free) Proprietary Formulation	03-27	MT
Avicanna Brief: Announcing Canadian Launch of 10% CBD (THC Free) Proprietary Formulation	03-27	MT
Avicanna Inc Announces the Canadian Launch of 10% CBD (THC Free) Proprietary Formulation	03-27	CI
ThreeD Capital Inc. Announces New YouTube Channel	03-25	MT
Avicanna Reports New Research Collaboration With Multi-national European-based Pharmaceutical Firm; Down 5.6%	02-15	MT
Avicanna Reports New Research Collaboration With Multi-national European-based Pharmaceutical Firm	02-15	MT
Avicanna Brief: Announcing New Research Collaboration with a Multi-national European-based Pharmaceutical Company	02-15	MT
Avicanna Inc. Announces New Research Collaboration with a Multi-National European-Based Pharmaceutical Company	02-15	CI
Avicanna Brief: Adds Approval issued by the Health Authority of Colombia INVIMA for Adjuvant treatment for seizures associated with Lennox-Gastaut Syndrome (LGS) and Dravet Syndrome (DS)	02-13	MT
Avicanna Brief: Says Obtained Its First Indication-Specific Drug Registration with Trunerox	02-13	MT
Avicanna Inc. Obtains Its First Indication-Specific Drug Registration with Trunerox	02-13	CI

Chart Avicanna Inc.

Duration

Period

More charts

Company Profile

Avicanna Inc. is a Canada-based commercial-stage international biopharmaceutical company. The Company's scientific platform commercializes over thirty products across various market segments: Medical Cannabis & Wellness Products (RHO Phyto), Pharmaceutical Pipeline and Medical Cannabis Care Platform (MyMedi.ca). RHO Phyto formulary offers a diverse range of proprietary formulations, including oral, sublingual, topical and transdermal delivery. It has developed a pipeline of patent-pending drug candidates that are indication specific and in various stages of clinical development and commercialization. These cannabinoid-based drug candidates look to address unmet medical needs in the areas of dermatology, chronic pain and various neurological disorders. Its first pharmaceutical preparation (Trunerox) is in the drug registration stage in South America. MyMedi.ca is a medical cannabis care platform that serves medical cannabis patientsâ needs and enhances the patient's journey.

Sector

Biotechnology & Medical Research

Calendar

2024-07-09 - Annual General Meeting

More about the company

Income Statement Evolution

More financial data

Annual profits - Rate of surprise

Company calendar

Sector Other Biotechnology & Medical Research

	1st Jan change	Capi.
AVICANNA INC.	-27.14%	17.78M
MODERNA, INC.	+47.88%	56.87B
LONZA GROUP AG	+37.15%	39.72B
IQVIA HOLDINGS INC.	-6.34%	39.27B
CELLTRION, INC.	-6.90%	28.73B
ICON PUBLIC LIMITED COMPANY	+13.63%	26.21B
ALNYLAM PHARMACEUTICALS, INC.	-16.45%	19.79B
MEDPACE HOLDINGS, INC.	+32.56%	12.28B
UNITED THERAPEUTICS CORPORATION	+28.17%	12.23B
BIO-TECHNE CORPORATION	+0.51%	12.12B

Other Biotechnology & Medical Research